{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:25:38Z","timestamp":1787052338448,"version":"build-2736575974"},"reference-count":57,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Acne vulgaris is one of the most prevalent dermatological conditions, affecting up to 85% of individuals aged 11\u201330 years. Clascoterone cream is the first topical androgen receptor inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of acne vulgaris in patients aged 12 years and older, and the first agent in this class approved for use in both male and female patients. The aim of this narrative review is to summarize the current evidence regarding the efficacy, safety profile, and potential future applications of clascoterone in the treatment of acne vulgaris. A comprehensive literature search was conducted in PubMed\/MEDLINE and ClinicalTrials.gov databases up to April 2026. Search terms included \u201cclascoterone,\u201d \u201ccortexolone 17\u03b1-propionate,\u201d and \u201candrogen receptor inhibitor acne.\u201d Eligible publications included randomized controlled trials, meta-analyses, open-label extension studies, retrospective analyses, case reports, and relevant review articles published in English. Clinical trial registries and regulatory agency announcements were also searched for ongoing studies and recent approval decisions. Phase 3 trials and meta-analyses demonstrate that twice-daily application of clascoterone 1% cream significantly reduces inflammatory and non-inflammatory lesion counts compared to vehicle, with efficacy sustained up to 12 months of treatment. The safety profile is favorable, with adverse events limited predominantly to mild and transient local skin reactions. Subgroup analyses have shown no significant sex-related differences in efficacy or safety, and the safety profile appears comparable between adolescents and adults. In an exploratory pooled subgroup analysis, lesion-count reductions were greater in adults than in adolescents, whereas the adjusted between-group comparison of IGA success was not statistically significant. Because no formal treatment-by-age interaction test was reported, these findings should be considered hypothesis-generating. Emerging but still incomplete data suggest potential applications in androgenetic alopecia and mild hidradenitis suppurativa. Clascoterone represents a novel addition to the therapeutic armamentarium for acne vulgaris, offering a unique mechanism of action with a favorable safety profile. Further research is warranted to establish its role in combination therapies and in other androgen-dependent dermatoses.<\/jats:p>","DOI":"10.3390\/ph19081304","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:22:52Z","timestamp":1787048572000},"page":"1304","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clascoterone in the Treatment of Acne Vulgaris: A Narrative Review"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8393-905X","authenticated-orcid":false,"given":"Sara","family":"Shefa","sequence":"first","affiliation":[{"name":"Student Research Group of Experimental Dermatology, University Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9078-5830","authenticated-orcid":false,"given":"Jagoda","family":"Szwach","sequence":"additional","affiliation":[{"name":"Student Research Group of Experimental Dermatology, University Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3157-204X","authenticated-orcid":false,"given":"Anna","family":"Karwowska","sequence":"additional","affiliation":[{"name":"Student Research Group of Experimental Dermatology, University Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Wojno","sequence":"additional","affiliation":[{"name":"Student Research Group of Experimental Dermatology, University Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9622-1593","authenticated-orcid":false,"given":"Magdalena","family":"\u0141yko","sequence":"additional","affiliation":[{"name":"University Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0140-6736(11)60321-8","article-title":"Acne vulgaris","volume":"379","author":"Williams","year":"2012","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/jdv.20154","article-title":"Efficacy of topical treatments for mild-to-moderate acne: A systematic review and meta-analysis of randomized control trials","volume":"39","author":"Kakpovbia","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bjd.12149","article-title":"Epidemiology of acne vulgaris","volume":"168","author":"Bhate","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/bmj.298.6682.1217","article-title":"Acne in schoolchildren: No longer a concern for dermatologists","volume":"298","author":"Rademaker","year":"1989","journal-title":"Br. Med. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0190-9622(98)70442-6","article-title":"Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris","volume":"39","author":"White","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.clindermatol.2009.03.012","article-title":"The role of Propionibacterium acnes in acne pathogenesis: Facts and controversies","volume":"28","author":"Dessinioti","year":"2010","journal-title":"Clin. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jaad.2007.08.049","article-title":"Milk consumption and acne in teenaged boys","volume":"58","author":"Adebamowo","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1468-3083.2010.03590.x","article-title":"The epidemiology of adolescent acne in North East China","volume":"24","author":"Wei","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jaad.2005.03.029","article-title":"Socioeconomic status influences care of patients with acne in Ontario, Canada","volume":"54","author":"Haider","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1525-1470.2006.00276.x","article-title":"A single-blinded, randomized, controlled clinical trial evaluating the effect of face washing on acne vulgaris","volume":"23","author":"Choi","year":"2006","journal-title":"Pediatr. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.1365-2133.2001.04290.x","article-title":"Epidemiology of acne in the general population: The risk of smoking","volume":"145","author":"Schafer","year":"2001","journal-title":"Br. J. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0022-3999(83)90021-1","article-title":"Treatment of acne vulgaris by biofeedback relaxation and cognitive imagery","volume":"27","author":"Hughes","year":"1983","journal-title":"J. Psychosom. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1006.e1","DOI":"10.1016\/j.jaad.2023.12.017","article-title":"Guidelines of care for the management of acne vulgaris","volume":"90","author":"Reynolds","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bjd.21739","article-title":"A systematic review and network meta-analysis of topical pharmacological, oral pharmacological, physical and combined treatments for acne vulgaris","volume":"187","author":"Mavranezouli","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s40265-020-01417-6","article-title":"Clascoterone: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1039\/C4MD00049H","article-title":"A full conformational characterization of antiandrogen cortexolone-17\u03b1-propionate and related compounds through theoretical calculations and nuclear magnetic resonance spectroscopy","volume":"5","author":"Ferraboschi","year":"2014","journal-title":"MedChemComm"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jaad.2020.04.087","article-title":"Open-label, long-term extension study to evaluate the safety of clascoterone cream, 1% twice daily, in patients with acne vulgaris","volume":"83","author":"Eichenfield","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jamadermatol.2020.0465","article-title":"Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients with Facial Acne: Two Phase 3 Randomized Clinical Trials","volume":"156","author":"Hebert","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_19","unstructured":"U.S. Food and Drug Administration (2026, April 13). WINLEVI (Clascoterone) Cream, 1% Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213433s000lbl.pdf."},{"key":"ref_20","first-page":"104587","article-title":"Clascoterone 1% in the Treatment of Acne: A Review of its Efficacy, Safety, and Therapeutic Positioning","volume":"117","year":"2025","journal-title":"Actas Dermosifiliogr."},{"key":"ref_21","first-page":"34","article-title":"Overview of the Efficacy and Safety of Topical Hormonal Therapies for the Treatment of Acne Vulgaris: A Narrative Review","volume":"19","author":"Baldwin","year":"2026","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2165\/00128071-200203080-00007","article-title":"Acne","volume":"3","author":"Shaw","year":"2002","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_23","first-page":"1005","article-title":"Androgens have forgotten and emerging roles outside of their reproductive functions, with implications for diseases and disorders","volume":"1","author":"Dart","year":"2014","journal-title":"Austin J. Endocrinol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00403-012-1265-x","article-title":"The role of androgen and androgen receptor in skin-related disorders","volume":"304","author":"Lai","year":"2012","journal-title":"Arch. Dermatol. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1358\/dot.2023.59.2.3507749","article-title":"Clascoterone for treatment of acne","volume":"59","author":"Manjaly","year":"2023","journal-title":"Drugs Today"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"174","DOI":"10.36849\/JDD.7000","article-title":"Efficacy and Safety of 1% Clascoterone Cream in Patients Aged \u2265 12 Years with Acne Vulgaris","volume":"22","author":"Hebert","year":"2023","journal-title":"J. Drugs Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1007\/s13555-025-01495-y","article-title":"Reduction in Facial Sebum Production Following Treatment with Clascoterone Cream 1% in Patients with Acne Vulgaris: 12-Week Interim Analysis","volume":"15","author":"Draelos","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"810","DOI":"10.36849\/jdd.7592","article-title":"Long-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients \u226512 Years of Age With Acne Vulgaris","volume":"22","author":"Eichenfield","year":"2023","journal-title":"J. Drugs Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.36849\/JDD.7719","article-title":"Integrated Short-Term and Long-Term Efficacy of Topical Clascoterone Cream 1% in Patients Aged 12 Years or Older with Acne Vulgaris","volume":"23","author":"Eichenfield","year":"2024","journal-title":"J. Drugs Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/CCID.S498879","article-title":"Real-World Experience of Clascoterone Cream 1% in Acne Management: Case Series and Canadian Experience","volume":"18","author":"Tay","year":"2025","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s13555-024-01324-8","article-title":"Hormonal Therapies for Acne: A Comprehensive Update for Dermatologists","volume":"15","author":"Smith","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Basendwh, M.A., Alharbi, A.A., Bukhamsin, S.A., Abdulwahab, R.A., and Alaboud, S.A. (2024). The efficacy of Topical Clascoterone versus systematic spironolactone for treatment of acne vulgaris: A systematic review and network meta-analysis. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0298155"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s13555-024-01175-3","article-title":"Comparison of the Efficacy of Clascoterone, Trifarotene, and Tazarotene for the Treatment of Acne: A Systematic Literature Review and Meta-Analysis","volume":"14","author":"Shergill","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e14609","DOI":"10.1111\/dth.14609","article-title":"Efficacy and safety of topical clascoterone cream for treatment of acne vulgaris: A systematic review and meta-analysis of randomized placebo-controlled trials","volume":"34","author":"Alkhodaidi","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_35","first-page":"20","article-title":"Prospective Pilot Evaluation of the Safety, Tolerability, and Efficacy of Clindamycin Phosphate 1.2%\/Adapalene 0.15%\/Benzoyl Peroxide 3.1% Gel plus Clascoterone 1% Cream in Adult Patients with Acne","volume":"18","author":"Yu","year":"2025","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_36","first-page":"22","article-title":"Clascoterone Cream 1% in Acne Management: Case Series and Real-World Canadian Experience","volume":"6","author":"Loo","year":"2025","journal-title":"Can. Dermatol. Today"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.36849\/JDD.9388","article-title":"Efficacy and Safety of Clascoterone Cream 1% for Acne Are Independent of Age and Sex","volume":"25","author":"Libecco","year":"2026","journal-title":"J. Drugs Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1365-4632.2010.04416.x","article-title":"Large-scale worldwide observational study of adherence with acne therapy","volume":"49","author":"Thiboutot","year":"2010","journal-title":"Int. J. Dermatol."},{"key":"ref_39","first-page":"412","article-title":"Cortexolone 17\u03b1-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro","volume":"18","author":"Rosette","year":"2019","journal-title":"J. Drugs Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jaad.2023.08.064","article-title":"Clascoterone in the treatment of mild hidradenitis suppurativa","volume":"90","author":"Hargis","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2525287","DOI":"10.1080\/09546634.2025.2525287","article-title":"Efficacy of oral isotretinoin monotherapy compared to combination isotretinoin and topical clascoterone for severe acne vulgaris: A multi-center retrospective study","volume":"36","author":"Choi","year":"2025","journal-title":"J. Dermatol. Treat."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/cpdd.935","article-title":"A Phase 1 Study to Investigate the Effects of Cortexolone 17\u03b1-Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity","volume":"10","author":"Mazzetti","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_43","first-page":"20","article-title":"Is There a Clinically Relevant Risk of Hyperkalemia with Topical Clascoterone Treatment?","volume":"16","author":"Squittieri","year":"2023","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/cpdd.1561","article-title":"Pharmacokinetics, Safety, and Skin Irritation and Sensitization Potential of Clascoterone Cream in Early-Phase Clinical Study Participants","volume":"14","author":"Radicioni","year":"2025","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"433","DOI":"10.36849\/JDD.7997","article-title":"Hypothalamic-Pituitary-Adrenal Axis Response in Patients with Acne Vulgaris Treated with Clascoterone","volume":"23","author":"Bhatia","year":"2024","journal-title":"J. Drugs Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jdcr.2025.11.036","article-title":"Perioral dermatitis secondary to topical clascoterone 1%","volume":"68","author":"Noda","year":"2026","journal-title":"JAAD Case Rep."},{"key":"ref_47","first-page":"45","article-title":"Severe acne induced by clascoterone: A case report","volume":"71","author":"Castillo","year":"2026","journal-title":"JAAD Case Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/ced.14292","article-title":"Clascoterone as a novel treatment for androgenetic alopecia","volume":"45","author":"Sun","year":"2020","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_49","first-page":"305","article-title":"A summary of in vitro, phase I, and phase II studies evaluating the mechanism of action, safety, and efficacy of clascoterone in androgenetic alopecia","volume":"9","author":"Mazzetti","year":"2019","journal-title":"J. Cosmet. Dermatol. Sci. Appl."},{"key":"ref_50","unstructured":"Cosmo Pharmaceuticals N.V. (2026, June 18). Cosmo announces breakthrough Phase III topline results from SCALP 1 and SCALP 2 for clascoterone 5% solution in male hair loss, showing up to 539% relative improvement in Target-Area Hair Count versus placebo. Press Release. Available online: https:\/\/www.cosmohealthconfidence.com\/news\/11029858-breezula-phase-iii-results."},{"key":"ref_51","unstructured":"Cosmo Pharmaceuticals N.V. (2026, June 18). Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth. Press Release. Available online: https:\/\/www.cosmohealthconfidence.com\/news\/98958067-clascoterone-12-month-safety-results-ende."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jdcr.2023.04.002","article-title":"Use of topical clascoterone for the treatment of hidradenitis suppurativa","volume":"36","author":"Cunningham","year":"2023","journal-title":"JAAD Case Rep."},{"key":"ref_53","unstructured":"Narrows Institute for Biomedical Research (2026, June 18). Efficacy and Safety of Topical Clascoterone Cream 1% in Patients with Facial Acneiform Rosacea. ClinicalTrials.gov Identifier: NCT06952517, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06952517."},{"key":"ref_54","unstructured":"Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd (2026, June 18). Efficacy and Safety of Clascoterone Cream 1% in Treatment of Subjects with Facial Acne Vulgaris. ClinicalTrials.gov Identifier: NCT06403501, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06403501."},{"key":"ref_55","unstructured":"University of Pennsylvania (2026, June 18). Topical Anti-Androgens in Pilonidal Sinus Disease. ClinicalTrials.gov Identifier: NCT06286397, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06286397."},{"key":"ref_56","unstructured":"Sun Pharmaceutical Industries Limited (2026, June 18). Histologic and Liquid Chromatography Mass Spectrometry (LCMS) Evaluation of the Sebaceous Gland Changes Induced by Clascoterone Cream 1%. ClinicalTrials.gov Identifier: NCT06425900, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06425900."},{"key":"ref_57","unstructured":"Chang, A. (2026, June 18). Topical Androgen Receptor Inhibitor for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy. ClinicalTrials.gov Identifier: NCT05891795, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05891795."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/8\/1304\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:29:13Z","timestamp":1787048953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/8\/1304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":57,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ph19081304"],"URL":"https:\/\/doi.org\/10.3390\/ph19081304","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}